China
Africa
Explore chapters and articles related to this topic
Bioresponsive Nanoparticles
Published in Deepa H. Patel, Bioresponsive Polymers, 2020
Drashti Pathak, Deepa H. Patel
For example, according to the National Breast Cancer Foundation, the fight against breast cancer is not a fight against a single disease, but a fight against no less than seven major subclasses of breast cancer (Ductal Carcinoma In-situ, Infiltrating Ductal Carcinoma, Medullary Carcinoma, Infiltrating Lobular Carcinoma, Tubular Carcinoma, Mucinous Carcinoma, and Inflammatory Breast Cancer). Each of these types of breast cancer are classified based on what type of tissue the cancer first develops in as well as physical characteristics of the tumors or cancer cells themselves.
Endocrine mucin-producing sweat gland carcinoma: a systematic review and meta-analysis
Published in Journal of Dermatological Treatment, 2022
Michael H. Froehlich, Keith R. Conti, Ivy I. Norris, Jordan J. Allensworth, Nicole A. Ufkes, Shaun A. Nguyen, Evelyn T. Bruner, Joel Cook, Terry A. Day
The results demonstrated that 41.6% of lesions evaluated had co-existent IMC, the histologic pattern seen in PCMC. Zembowicz et al. reported 12 cases of EMPSGC, of which 50% also had components of IMC. The authors suggested that EMPSGC likely has the capacity to progress from an in-situ tumor with minimal mucous production, to an invasive carcinoma, PCMC, with cells suspended in pools of mucin (2). This observation led many to believe that EMPSGC and PCMC exist along a progressive spectrum of disease. EMPSGC is histologically analogous to solid papillary carcinoma, a well-established precursor to mucinous carcinoma of the breast. Therefore, just as solid papillary carcinoma of the breast progresses into a mucinous carcinoma, it is suggested that EMPSGC may behave in the same manner by progressing to PCMC (1,35).
Simultaneous upper limb melanoma and breast cancer related lymphedema management
Published in Case Reports in Plastic Surgery and Hand Surgery, 2023
Dimitrios Dionyssiou, Athanasios Papas, Avra Drougou, Athanasios Tsamaldoupis, Georgios Arsos, Efterpi Demiri
She had a history of left breast cancer, four years ago, for which she had undergone a tumorectomy. Due to a BC recurrence in a year, she underwent a neoadjuvant chemotherapy according to the standard of care related to that period, followed by left mastectomy with ipsilateral axillary lymph node dissection (ALND). The histopathologic examination showed a moderately differentiated invasive mucinous carcinoma of the breast (Elston and Ellis grade 2), with micropapillary features to a lesser extent. Three out of ten excised lymph nodes were positive, which led to a postoperative axillary region radiotherapy. BRCA gene mutation testing was positive and decided a contralateral prophylactic mastectomy along with laparoscopic prophylactic oophorectomy one year later.